Cho Yong Beom, Lee Kuhn Uk, Suh Kyung-Suk, Kim Yoon Jun, Yoon Jung-Hwan, Lee Hyo-Suk, Hahn Seokyung, Park Byung-Joo
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
J Gastroenterol Hepatol. 2007 Oct;22(10):1643-9. doi: 10.1111/j.1440-1746.2007.04902.x.
Several surgical and non-surgical therapeutic modalities have been used for the treatment of hepatocellular carcinoma (HCC). There have been several studies comparing hepatic resection (HR) and percutaneous ethanol injection (PEI) for the treatment of HCC. However, there is still disagreement about the best treatment modality.
From 130 patients undergoing HR, 116 patients were individually matched to 116 controls from 249 patients undergoing PEI using propensity score matching to overcome possible biases in non-randomized study. Survival analyses were undertaken to compare these propensity score-matched groups.
After matching by propensity score, the major clinical outcomes in the HR (n = 116) and the PEI (n = 116) groups were found to be similar. The 1-, 3- and 5-year overall survival rates were higher in the HR group (94.8%, 76.5% and 65.6%) compared to the PEI group (95.7%, 73.5% and 49.3%) (P = 0.059). The cumulative 1-, 3- and 5-year disease-free survival rates showed the same trend (HR: 76.1%, 50.6% and 40.6%; PEI: 62.6%, 25.5% and 19.1%) (P < 0.001). However, when stratified by Child-Pugh classification, it was no longer the case in the Child B patients. Single intrahepatic recurrence was the most common pattern of tumor recurrence after both treatments.
Patients undergoing HR had a better survival profile than those undergoing PEI. However, when considering which technique to use for optimal HCC management, the individual patient's hepatic function must be considered.
多种手术和非手术治疗方式已用于肝细胞癌(HCC)的治疗。已有多项研究比较肝切除术(HR)和经皮乙醇注射(PEI)治疗HCC的效果。然而,对于最佳治疗方式仍存在分歧。
从130例行HR的患者中,使用倾向评分匹配法从249例行PEI的患者中选出116例对照,以克服非随机研究中可能存在的偏差。对这些倾向评分匹配组进行生存分析以作比较。
经倾向评分匹配后,发现HR组(n = 116)和PEI组(n = 116)的主要临床结局相似。HR组的1年、3年和5年总生存率分别为94.8%、76.5%和65.6%,高于PEI组的95.7%、73.5%和49.3%(P = 0.059)。累积1年、3年和5年无病生存率也呈现相同趋势(HR组:76.1%、50.6%和40.6%;PEI组:62.6%、25.5%和19.1%)(P < 0.001)。然而,按Child-Pugh分级分层后,Child B级患者并非如此。两种治疗后,单个肝内复发是最常见的肿瘤复发模式。
行HR的患者比行PEI的患者有更好的生存情况。然而,在考虑采用哪种技术进行最佳HCC治疗时,必须考虑个体患者的肝功能。